First Patient Treated Worldwide with the new CyberKnife® M6™ System

     First Patient Treated Worldwide with the new CyberKnife® M6™ System

  PR Newswire

  SUNNYVALE, California, Feb. 4, 2013

-- European CyberKnife Center to Offer Patients Advanced Radiosurgery
Treatments in Munich

SUNNYVALE, California, Feb. 4, 2013 /PRNewswire/ -- Accuray Incorporated
(Nasdaq: ARAY), a radiation oncology company, announced today that the
European CyberKnife Center Munich-Grosshadern (ECZM) has treated the world's
first patient with the new CyberKnife® M6™ System. With the installation of
the new system, the Munich center, in close cooperation with the University
Hospital of Munich, is the first to offer cancer patients treatment with the
CyberKnife M6 System, the latest generation of the CyberKnife System. The new
System is now able to provide enhanced quality, a streamlined user interface
for treatment delivery and precision to radiation therapy treatments and
continues to provide clinical capabilities including non-isocentric,
non-coplanar robotic beam delivery and real-time tracking and automatic

"We are pleased to have installed the first CyberKnife M6 System at the
European CyberKnife Center Munich-Grosshadern," said Joshua H. Levine,
president and chief executive officer of Accuray Incorporated. "The CyberKnife
M6 System is the next generation system and will enable clinicians to provide
cancer patients with truly personalized treatments."

The ECZM is a global pioneer in radiosurgery. Back in 2005, the center was the
first in Germany to have installed a CyberKnife System. As of today, the team
of clinicians has treated more than 3,500 patients for intra- and extracranial
tumors using CyberKnife SBRT.

"It is vital to offer our patients the best possible care. With the CyberKnife
System, we know from experience that extremely accurate outcomes can be
achieved. The new system enables us to treat patients significantly faster.
Also the treatment will be available to a much bigger patient population. With
the CyberKnife Systems we are able to adapt the treatment accurately to the
individual needs of each patient's indication," said Prof. Dr. Berndt Wowra,
Neurosurgeon and Radiosurgeon.

Dr. Alexander Muacevic, Neurosurgeon, Radiosurgeon and president of the
Radiosurgery Society, added: "We will now be able to not only treat small,
well-circumscribed tumors, but also larger and irregularly-shaped target

About the European CyberKnife Center, Germany The European CyberKnife Center
Munich (ECZM) was the first center to have a CyberKnife® system installed in
Germany. Opened in 2005, it maintains several close scientific and clinical
partnerships among which are the University Hospital Charite Berlin and the
Stanford University, California/USA. Moreover, the ECZM clinically and
scientifically cooperates with the University Clinic of Munich
(Ludwig-Maximilians-Universitat, LMU), which contributed significantly to the
further development of the technology and the treatment of various indications
with CyberKnife®. Until today, the center's team has treated more than 3,500
patients, most of them (71%) for intracranial lesions or tumors. As part of
the Radiosurgery Society, the team has accompanied and published many clinical
studies (covering topics like e.g. the treatment of spinal tumors, brain
metastases or vestibular schwannoma) for which it is perceived as a pioneer of
radiosurgery in Germany. For more information please visit .

About Accuray Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology
company that develops, manufactures and sells personalized, innovative
treatment solutions that set the standard of care with the aim of helping
patients live longer, better lives. The Company's leading-edge technologies
deliver the full range of radiation therapy and radiosurgery treatments.

Safe Harbor Statement Statements made in this press release that are not
statements of historical fact are forward-looking statements and are subject
to the "safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995. Forward-looking statements in this press release relate, but are
not limited, to clinical applications, clinical results, patient outcomes, and
the Company's leadership position in radiation oncology innovation.
Forward-looking statements are subject to risks and uncertainties that could
cause actual results to differ materially from expectations, including risks
detailed from time to time under the heading "Risk Factors" in the company's
report on Form 10-K filed on September 10, 2012, as updated in our Form 10-Q
filed on November 8, 2012 and as updated periodically by our other filings.
Forward-looking statements speak only as of the date the statements are made
and are based on information available to the Company at the time those
statements are made and/or management's good faith belief as of that time with
respect to future events. The Company assumes no obligation to update
forward-looking statements to reflect actual performance or results, changes
in assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities laws.
Accordingly, investors should not place undue reliance on any forward-looking

Contact: Anja Kleber, Marketing Director, + 33 (0) 1 55 23 20 20,; or Nadine Gottschling, Edelman Germany, + 49 (0) 69 75 61
99 76,
Press spacebar to pause and continue. Press esc to stop.